BioDelivery Sciences International, Inc. News Releases http://ir.bdsi.com/ BioDelivery Sciences International, Inc. News Releases en BioDelivery Sciences Expands Upon Report from Pain Management Task Force http://ir.bdsi.com/news-releases/news-release-details/biodelivery-sciences-expands-upon-report-pain-management-task Company’s Activities Support Buprenorphine Recommendations Including: Primary Use of Buprenorphine in Chronic Pain when Clinically Indicated Having Payers Provide Coverage and Reimbursement for Buprenorphine for Chronic Pain RALEIGH, N.C. , June 24, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences Mon, 24 Jun 2019 08:00:00 -0400 BioDelivery Sciences International, Inc. News Releases 13216 BioDelivery Sciences Named to the Russell 3000® Index http://ir.bdsi.com/news-releases/news-release-details/biodelivery-sciences-named-russell-3000r-index Recognition is a Result of Company’s Performance over the Last 12 Months RALEIGH, N.C. , June 20, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI) is set to be added to the broad-market Russell 3000 ®  Index as well as the Russell 2000 ® Index at the conclusion of Thu, 20 Jun 2019 08:00:00 -0400 BioDelivery Sciences International, Inc. News Releases 13191 BioDelivery Sciences Announces Upcoming Investor Conference Presentations http://ir.bdsi.com/news-releases/news-release-details/biodelivery-sciences-announces-upcoming-investor-conference RALEIGH, N.C. , May 29, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions today announced that Herm Cukier , Chief Executive Officer will present Wed, 29 May 2019 16:10:00 -0400 BioDelivery Sciences International, Inc. News Releases 13161 BioDelivery Sciences Strengthens Financial Position with Debt Refinancing http://ir.bdsi.com/news-releases/news-release-details/biodelivery-sciences-strengthens-financial-position-debt New Agreement is Cash Flow Accretive, Lowers Cost of Capital and Extends Debt Maturity Reduces Annual Interest Costs by Approximately $1.5 million Increases Flexibility to Continue Growth Trajectory RALEIGH, N.C. , May 28, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. Tue, 28 May 2019 16:10:00 -0400 BioDelivery Sciences International, Inc. News Releases 13141 BioDelivery Sciences Reports Strong First Quarter 2019 Results and Raises BELBUCA® Full-Year Expectations http://ir.bdsi.com/news-releases/news-release-details/biodelivery-sciences-reports-strong-first-quarter-2019-results BELBUCA ® Net Sales Increased by 134% versus Prior Year to All-time High of $18.7 Million Symproic ® Acquisition and Commercial Integration Successfully Completed Company Raises Full-Year BELBUCA Net Sales Expectations to $83 - $88 Million Confirms Full-Year Net Sales Expectations of $92 - $100 Mon, 06 May 2019 16:05:00 -0400 BioDelivery Sciences International, Inc. News Releases 13101 BioDelivery Sciences to Report First Quarter 2019 Financial Results http://ir.bdsi.com/news-releases/news-release-details/biodelivery-sciences-report-first-quarter-2019-financial-results RALEIGH, N.C. , April 25, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients living with chronic pain, today announced that it will report its first quarter 2019 financial Thu, 25 Apr 2019 16:30:00 -0400 BioDelivery Sciences International, Inc. News Releases 13086 BioDelivery Sciences International, Inc. Announces Pricing of Public Offering of Common Stock http://ir.bdsi.com/news-releases/news-release-details/biodelivery-sciences-international-inc-announces-pricing-public RALEIGH, N.C. , April 11, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) (“BDSI” or the “Company”) today announced the pricing of an underwritten public offering by the Company and a selling stockholder of 12,000,000 shares of common stock at a public offering Thu, 11 Apr 2019 09:29:00 -0400 BioDelivery Sciences International, Inc. News Releases 13051 BioDelivery Sciences International, Inc. Announces Proposed Underwritten Public Offering of Common Stock http://ir.bdsi.com/news-releases/news-release-details/biodelivery-sciences-international-inc-announces-proposed RALEIGH, N.C. , April 10, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) (“BDSI” or the “Company”) today announced that it is commencing an underwritten public offering of shares of common stock. In addition, the underwriters will have a 30-day option to purchase Wed, 10 Apr 2019 16:07:00 -0400 BioDelivery Sciences International, Inc. News Releases 13036 BioDelivery Sciences Acquires U.S. Commercial Rights to Symproic® http://ir.bdsi.com/news-releases/news-release-details/biodelivery-sciences-acquires-us-commercial-rights-symproicr Long-term revenue potential of over $75 million for NME with IP protection through 2031 Leverages existing commercial capabilities to provide a novel treatment option for OIC  Total 2019 Company Net Sales expected to be $92-$100 million with Symproic Net Sales of $7-$9 million Long-term potential Wed, 10 Apr 2019 16:06:00 -0400 BioDelivery Sciences International, Inc. News Releases 13031 BioDelivery Sciences Reports Strong 2018 Results and 2019 Expectations http://ir.bdsi.com/news-releases/news-release-details/biodelivery-sciences-reports-strong-2018-results-and-2019 Thu, 14 Mar 2019 16:15:00 -0400 BioDelivery Sciences International, Inc. News Releases 12991